EFFECT OF DMP 266 ON HEPATIC AND INTESTINAL CYP3A ACTIVITY

在动物研究中，已经证明了BMP 266诱导其自身的 代谢和增加肝脏CYP 3A和CYP 2B酶活性。 在 在人类中，CYP 3A 4是存在的主要I相代谢酶 在肝脏和肠道，现有的数据表明，它可能 第266章被逼无奈 为了明确地确定情况是否如此， 将24名健康志愿者随机接受200 mg/kg的地塞米松266（200 mg/kg）或200 mg/kg的地塞米松266（200 mg/kg）。 mg或400 mg/天）或安慰剂口服10天。 肠活检组织 将在首次给药前和给药后第二天获得 第10次注射。 此外，单次静脉给药 [14-C-N-甲基]红霉素将在9个不同的 在整个研究过程中。

In animal studies, DMP 266 has been demonstrated to induce its own metabolism and increase hepatic CYP3A and CYP2B enzyme activities. In humans, CYP3A4 is the predominant phase-I metabolizing enzyme present in the liver and intestine, and the available data suggest that it may be induced by DMP 266. To definitively determine if this is the case, 24 healthy volunteers will be randomized to receive either DMP 266 (200 mg or 400 mg/daily) or placebo orally for 10 days. Intestinal biopsies will be obtained prior to the first dose of DMP 266 and on the day after administration of the 10th dose. In addition, single intravenous doses of [14-C-N-methyl] erhthromycin will be administered on 9 different occasions throughout the study.